Quantum Machine Learning

Expected Outcome: the proposals under this call are expected to address one or more of the following subjects : • Enhanced personalized monitoring, care and treatments, focusing on the development of highly customized healthcare solutions, including the required research and diagnostic tools, tailored to individual needs, covering various scenarios such as chronic disease management, physiotherapy, precision diagnosis, personalized medicine/treatment, pre- and postoperative care, and daily assistance in homes and common spaces. It also targets effective management of chronic diseases and elderly care through personalized monitoring and interventions facilitated by advanced sensor technologies and edge-to-cloud solutions. This includes the development and integration of solutions for Hospitalization at Home, enabling patients to receive complex, remotely supervised care using intelligent medical devices capable of sensing, analysing, and transmitting real-time data. This requires a continuum, from in-hospital diagnostics to robust, long-term patient support at home via AI-driven care pathways and hospitalization at home. • Prevention and treatment of diseases, allowing the improved…

Expected Outcome: Proposals submitted to this call are expected to address several of the following elements: • Scaling of wafer-level photonic processes for key materials (e.g. SiN, InP, GaAs),including process integration, yield optimisation, and manufacturability at highvolumes. • Development of packaging and test solutions that are scalable, automated, andcompatible with co-packaged optics and advanced photonic-electronic integration. • Integration of heterogeneous materials and components, such as on-chip lasers,modulators, and detectors, using advanced packaging and assembly approaches. • Design-process-equipment co-optimisation, enabling repeatable, cost-effectiveproduction of complex photonic circuits and systems, including use of PDKs andvalidated building blocks. • Demonstration of system-level functionality through application-relevant use casesin strategic sectors (e.g. AI, sensing, telecommunication, mobility, health, defence),with quantified performance metrics and clear market relevance.

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Outcome: Project results are expected to contribute to all of the following expected outcomes: Implementation of the NWRSA methodology for secondary rural roads; Innovative and effective enforcement strategies, incentive mechanisms and measures raising risk awareness for fostering safer behaviour; Prevention strategies for reducing road fatalities and serious road traffic injuries on rural roads along with the respective implementation guidelines and policy measures tailored to the responsible stakeholders (regional authorities, police, healthcare professionals, national governments, etc.); GIS-based application to assist local and regional authorities in identifying and mapping the impact of extreme weather phenomena and other natural disasters (such as floods, fires, storms, heavy snowfall etc.) on the safety and resilience of the road network in their jurisdiction. Scope: With more than 50% of all EU road fatalities occurring in rural areas along with evidence suggesting that crashes and crash-related fatalities in rural roads vary from those in urban roads or motorways, it is imperative to understand and mitigate the safety risks in rural roads in view of the EU’s…

Specific Challenge: The “EU Award for Gender Equality Champions” is a recognition prize scheme designed as a booster and a complement to the Gender Equality Plans (GEP) eligibility criterion in Horizon Europe [1] , and as a tool for advancing inclusive GEPs and policies within the framework of the ERA Policy Agenda. Expected Outcomes : Recognition of organisations with the most significant impact resulting from the implementation of their GEP, serving as role models for others; Strengthened gender equality and inclusiveness in the European Research Area. The Prize will be awarded to four organisations, and contestants can apply to one of the following three prize categories: Sustainable Gender Equality Champions: Organisations that can demonstrate a significant and sustained record of activity and a high level of achievement through the implementation of their GEP(s); Newcomer Gender Equality Champions: Organisations without a sustained record of activity in gender equality that have recently completed the implementation of their first GEP and can demonstrate the most progress achieved through its implementation; Inclusive Gender Equality Champions: Organisations that have…

Specific Challenge: The “EU Award for Gender Equality Champions” is a recognition prize scheme designed as a booster and a complement to the Gender Equality Plans (GEP) eligibility criterion in Horizon Europe [1] , and as a tool for advancing inclusive GEPs and policies within the framework of the ERA Policy Agenda. Expected Outcomes : Recognition of organisations with the most significant impact resulting from the implementation of their GEP, serving as role models for others; Strengthened gender equality and inclusiveness in the European Research Area. The Prize will be awarded to four organisations, and contestants can apply to one of the following three prize categories: Sustainable Gender Equality Champions: Organisations that can demonstrate a significant and sustained record of activity and a high level of achievement through the implementation of their GEP(s); Newcomer Gender Equality Champions: Organisations without a sustained record of activity in gender equality that have recently completed the implementation of their first GEP and can demonstrate the most progress achieved through its implementation; Inclusive Gender Equality Champions: Organisations that have…

Specific Challenge: The “EU Award for Gender Equality Champions” is a recognition prize scheme designed as a booster and a complement to the Gender Equality Plans (GEP) eligibility criterion in Horizon Europe [1] , and as a tool for advancing inclusive GEPs and policies within the framework of the ERA Policy Agenda. Expected Outcomes : Recognition of organisations with the most significant impact resulting from the implementation of their GEP, serving as role models for others; Strengthened gender equality and inclusiveness in the European Research Area. The Prize will be awarded to four organisations, and contestants can apply to one of the following three prize categories: Sustainable Gender Equality Champions: Organisations that can demonstrate a significant and sustained record of activity and a high level of achievement through the implementation of their GEP(s); Newcomer Gender Equality Champions: Organisations without a sustained record of activity in gender equality that have recently completed the implementation of their first GEP and can demonstrate the most progress achieved through its implementation; Inclusive Gender Equality Champions: Organisations that have…

Expected Outcome: This action builds on the MSCA Doctoral Networks 2026 call (HORIZON-MSCA-DN-2026). The project results are expected to contribute to the following outcomes: For supported doctoral candidates: New research and transferable skills and competences in the application of AI in science, leading to improved employability and career prospects within and outside academia; New knowledge allowing the conversion of ideas into products and services, where relevant; Enhanced networking and communication capacities with scientific peers, as well as with the general public that will increase and broaden the research and innovation impact. For participating organisations: Improved quality, relevance and sustainability of doctoral training programmes and supervision arrangements; Enhanced cooperation and transfer of knowledge between sectors and disciplines; Increased integration of training and research activities between participating organisations; Boosted R&I capacity and uptake of AI in science; Increased internationalisation and attractiveness; Regular feedback of research results into teaching and education at participating organisations. Scope: Successful RAISE Doctoral…